MEDIPOST Secures FDA Agreement on Single Pivotal Phase 3 Study with Confirmatory Evidence BLA Filing Strategy for CARTISTEM® in the U.S.
SEOUL, South Korea, June 4, 2026 /PRNewswire/ -- MEDIPOST, a fully integrated commercial stage cell therapy biotechnology company, announced today that it has secured the FDA's agreement to conduct a...
Read more



![[Global Capital Opportunities] Global Investor Institute Officially Launched — Aims to Establish Hong Kong as the World Investors Hub](https://moneycompass.com.my/wp-content/uploads/2026/06/Picture1-I5e1yi-350x250.jpeg)



